MedPath

Dronabinol

Generic Name
Dronabinol
Brand Names
Marinol, Sativex, Syndros
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
1972-08-3
Unique Ingredient Identifier
7J8897W37S
Background

Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments .

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Dronabinol or Nabilone), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.

From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function .

Indication

Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions
Anorexia, Chemotherapy-Induced Nausea and Vomiting

Individual Differences in Drug Response

Early Phase 1
Completed
Conditions
Differential Female Response to Δ9-tetrahydrocannabinol (THC)
Interventions
First Posted Date
2019-01-18
Last Posted Date
2024-07-03
Lead Sponsor
University of Chicago
Target Recruit Count
60
Registration Number
NCT03809546
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

Developing a Mobile Method to Measure THC-induced Impairment

Early Phase 1
Completed
Conditions
Measuring THC-induced Cognitive Impairment Using a Mobile Application
Interventions
Drug: Placebo
First Posted Date
2019-01-15
Last Posted Date
2019-01-15
Lead Sponsor
University of Chicago
Target Recruit Count
48
Registration Number
NCT03804840
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

Dronabinol Opioid Sparing Evaluation (DOSE) Trial

Phase 2
Conditions
Chronic Pain
Interventions
First Posted Date
2018-12-06
Last Posted Date
2018-12-06
Lead Sponsor
Daisy Pharma Opioid Venture, LLC
Target Recruit Count
280
Registration Number
NCT03766269
Locations
🇺🇸

Daisy Research, Inc., Scottsdale, Arizona, United States

Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets

Early Phase 1
Completed
Conditions
Bone Metastases
Breast Cancer
Pain
Interventions
First Posted Date
2018-09-07
Last Posted Date
2021-04-29
Lead Sponsor
University of Arizona
Target Recruit Count
14
Registration Number
NCT03661892
Locations
🇺🇸

University of Arizona, Tucson, Arizona, United States

Using Imaging to Assess Effects of THC on Brain Activity

Not Applicable
Completed
Conditions
Intoxication Alcohol
Intoxication THC
Intoxication Combined Alcohol THC
Interventions
First Posted Date
2018-08-31
Last Posted Date
2022-07-28
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
316
Registration Number
NCT03655717
Locations
🇺🇸

Center for Addiction Medicine, Massachusetts General Hospital, Dept. of Psychiatry, Boston, Massachusetts, United States

Cannabinoids for Pain Control During Medical Abortion

Phase 4
Completed
Conditions
Pain
Medical Abortion
Interventions
First Posted Date
2018-07-27
Last Posted Date
2020-04-07
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
72
Registration Number
NCT03604341
Locations
🇺🇸

Oregon Health & Science University, Portland, Oregon, United States

Tetrahydrocannabinol (THC) and Sleep

Early Phase 1
Active, not recruiting
Conditions
Sleep
THC
Marijuana
Cannabis
Interventions
First Posted Date
2018-06-18
Last Posted Date
2024-04-15
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
18
Registration Number
NCT03560934
Locations
🇺🇸

Oregon Health & Science University, Portland, Oregon, United States

Effects of THC and Alcohol on Driving Performance

Phase 4
Withdrawn
Conditions
Cannabis
Alcohol Drinking
Accident, Traffic
Interventions
Other: BAC 0
Other: BAC .025
Other: BAC .049
First Posted Date
2018-06-14
Last Posted Date
2022-04-25
Lead Sponsor
Lakehead University
Registration Number
NCT03555968

Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors

Phase 2
Completed
Conditions
Skin-Picking
Trichotillomania
Interventions
Drug: Placebo
First Posted Date
2018-05-21
Last Posted Date
2022-06-02
Lead Sponsor
University of Chicago
Target Recruit Count
50
Registration Number
NCT03530800
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

Effects of THC on Emotional Memory Retrieval

Early Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo oral capsule
First Posted Date
2018-03-20
Last Posted Date
2019-05-30
Lead Sponsor
University of Chicago
Target Recruit Count
24
Registration Number
NCT03471585
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath